Gene Therapy Manufacturing

Overview

Manufacturing of gene and cell therapy products, characterized by small patient populations, complex regulatory requirements for prospective process validation, and the challenge of aligning CMC timelines with breakthrough clinical data in ultra-rare disease programs. Gene therapy manufacturing faces a structural bottleneck when breakthrough clinical data arrives with only 50-100 patients and existing material inventory is adequate: the FDA still requires prospective PPQ before a BLA can proceed, creating a mismatch between clinical urgency and manufacturing timelines. For the CD34 prime edited cell therapy, the mRNA and guide RNA components are classified by the FDA as critical reagents rather than drug substance, yet still require prospective process validation before a BLA, creating regulatory complexity for ultra-rare disease programs with minimal material needs. (Segment 5 (20:00-25:00))